Huangqi Jianzhong Tang |
CAG |
Network pharmacology and metabolomics |
Mitochondrial energy metabolism regulation |
108
|
Qilianshupi decoction |
CAG |
Network pharmacology and in vivo validation |
Survivin and p53 inhibition; regulation of telomerase activity and telomere length |
109
|
Modified Sijunzi decoction |
CAG |
Network pharmacology and clinical trial |
T-cell receptor beta regulation |
110
|
Huazhuojiedu decoction |
CAG |
Network pharmacology and in vivo validation |
Cancer-associated AKT1 pathway inhibition |
111
|
Moluodan |
CAG |
Network pharmacology and in vitro validation |
Inhibition of cell proliferation; promotion of cell differentiation and apoptosis; decreased inflammation; increased lipid droplet accumulation |
104
|
Banxia Xiexin decoction |
CAG |
Network pharmacology and in vitro dynamic validation |
Gastrin and MAPK signaling pathway regulation |
112
|
Manpixiao decoction |
LGD |
Network pharmacology and in vivo validation |
EGFR-PI3K-Akt-associated EMT pathway downregulation |
113
|
Weifuchun capsule |
CAG |
Network pharmacology and omics data and algorithms, and in vitro validation |
Inhibition of inflammatory cytokines; regulation of immune cells, such as T cells and macrophages; inflammation inhibition |
107
|